Filing Flows › Celldex Therapeutics (CLDX) › How it makes money
How Celldex Therapeutics (CLDX) makes money
Celldex Therapeutics (CLDX) made $22K of revenue in the second quarter 2026 (Q2 2026), -97% from a year earlier. Contracts and grants brought in $15K (68%); Product development and licensing agreements brought in $7K (32%).
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Contracts and grants | $15K | 68.2% | — | -98% |
| Product development and licensing agreements | $7K | 31.8% | — | 0% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $22K | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $22K | -97% |
| Q1 2026 | $15K | -98% |
| Q4 2025 | $121K | -90% |
| Q2 2025 | $730K | -71% |
| Q1 2025 | $695K | +346% |
| Q4 2024 | $1.2M | -72% |
From Celldex Therapeutics' 10-Q filed Aug 6, 2026 (on EDGAR).
Questions
How does Celldex Therapeutics make money?
Celldex Therapeutics (CLDX) made $22K of revenue in the second quarter 2026 (Q2 2026), -97% from a year earlier. Contracts and grants brought in $15K (68%); Product development and licensing agreements brought in $7K (32%).
What is Celldex Therapeutics' biggest business?
Contracts and grants: $15K in the second quarter 2026, 68% of revenue, -98% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.